Proof of Usefulness Report

Diagonal Therapeutics

Analysis completed on 1/28/2026

+794
Proof of Usefulness Score
Unicorn Utility

Diagonal Therapeutics is a legitimate, high-potential biotechnology company that has raised approximately $253M in funding (Series A and B) to develop clustering antibody therapies for rare genetic diseases like HHT and PAH. While the project itself demonstrates exceptional technical innovation, strong investor traction, and high real-world utility, the submission data contains significant inaccuracies (e.g., claiming 'everyone' as the audience and 'most people' as users, and listing a market cap of 500,000). The evaluation is based on the verified status of the company rather than the erroneous metadata provided.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+28.5
Audience Reach Impact+13.2
Technical Innovation+17.94
Evidence Of Traction+28.5
Market Timing Relevance+8.5
Functional Completeness+0.5
Subtotal+97.14
Usefulness Multiplierx0.82
Final Score+794

Project Details

Project URL
diagonaltx.com
Description
Diagonal Therapeutics is developing a new class of clustering antibody medicines designed to address the root causes of severe genetic diseases. Using our DIAGONAL platform, we engineer clustering bispecific antibodies to restore healthy cell signaling in genetically driven diseases. This innovative approach offers potential therapies that can modify disease biology, providing lasting benefits for patients with limited treatment options. Our lead program, DIAG723, targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH), two serious vascular diseases with significant unmet needs. It focuses on the dysregulated signaling that contributes to both conditions, showing promising results in early models. With strong investor support and a growing clinical pipeline, Diagonal Therapeutics is redefining treatment possibilities for challenging genetic diseases, moving beyond symptom relief to disease modification. Learn more at: www.diagonaltx.com

Algorithm Insights

Market Position
Strong market validation with clear user adoption patterns
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline